EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient

Yanan Wu, Runfang Zhang, Guangbo Yuan, Lingyu He, Xiaohu Dai, Hongyun Chuan, Mingqing Wang, Jing Liu, Lilan Xu, Guoyang Liao, Weidong Li, Jian Zhou

Viruses · 2024

DOI: 10.3390/v16111761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Yanan Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of…. Hauptthemen laut MEDLINE: Poliovirus, Antibodies, Neutralizing, Poliovirus Vaccine, Oral, Antibodies, Viral. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project of Medical and Health Science and Technology Innovation, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and spread, causing the emergence of vaccine-derived poliovirus (VDPV2) and immunodeficiency-related vaccine-derived polioviruses (iVDPVs). In the United States, testing carried out by the CDC of type II iVDPV (iVDPV2) with human immune serum from the vaccine has shown that the presence of the virus poses a threat to eradication efforts.

Methods

We analyzed the major neutralization sites of VP1, VP2, and VP3 of the iVDPV using bioinformatics techniques and homology modeling (SWISS-MODEL). The three amino acid residues 679, 680, and 141 of the P1 region changed, which had an impact on the spatial conformation of the viral-neutralizing site. We tested polio-vaccinated human sera and rabbit anti-Sabin II polyantibodies against a panel of iVDPV pseudoviruses.

Results

The results demonstrated that the serum’s capacity to neutralize mutant pseudoviruses diminished when amino acid substitutions were introduced into the P1 encapsidated protein, particularly when 141 and 679 were mutated together. This study emphasizes the significance of continually monitoring individuals who are known to be immunocompromised and maintaining high vaccination rates in OPV-using communities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PoliovirusAntibodies, NeutralizingPoliovirus Vaccine, OralAntibodies, ViralImmune SeraPoliomyelitisImmunocompromised HostHumansAnimalsCapsid ProteinsNeutralization TestsRabbits

Stichwörter der Autor:innen

immunogenicityneutralizing antibodiespolioviruspseudovirustype II

Substanzen

Antibodies, NeutralizingPoliovirus Vaccine, OralAntibodies, ViralImmune SeraCapsid Proteins

Autor:innen und Institutionen

  • Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China.
  • Institute of Medical Biology, Kunming Medical University, Kunming 650500, China.
  • Department of Industrial Transformation, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China.
  • Production Department, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China.

Förderung

  • Project of Medical and Health Science and Technology Innovation, Chinese Academy of Medical Sciences

Zitieren

APA

Wu, Y., Zhang, R., Yuan, G., He, L., Dai, X., Chuan, H., Wang, M., Liu, J., Xu, L., Liao, G., Li, W., & Zhou, J. (2024). Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient. Viruses. https://doi.org/10.3390/v16111761

Vancouver

Wu Y, Zhang R, Yuan G, He L, Dai X, Chuan H, et al. Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient. Viruses. 2024. doi:10.3390/v16111761

BibTeX
@article{Wu2024,
  author = {Wu, Yanan and Zhang, Runfang and Yuan, Guangbo and He, Lingyu and Dai, Xiaohu and Chuan, Hongyun and Wang, Mingqing and Liu, Jing and Xu, Lilan and Liao, Guoyang and Li, Weidong and Zhou, Jian},
  title = {Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16111761}
}
Kostenlos starten →